Several synthetic anti-obesity drugs are commercially available, such as orlistat, phentermine/topiramate, liraglutide, and naltrexone/bupropion, which were developed based on pancreatic lipase inhibition. This evidence concerns the gene PNLIP and obesity due to melanocortin 4 receptor deficiency.